TITAN PHARMACEUTICALS INC financial data

Symbol
TTNP
Location
San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q2 2025 - 14 Aug 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 840% % 23%
Debt-to-equity 14% % -21%
Return On Equity -109% % -24%
Return On Assets -96% % -27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,330,234 shares 46%
Common Stock, Shares, Outstanding 1,330,234 shares 46%
Entity Public Float $3,700,000 USD
Weighted Average Number of Shares Outstanding, Basic 1,065,000 shares 17%
Weighted Average Number of Shares Outstanding, Diluted 1,065,000 shares 17%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $2,611,000 USD -58%
Operating Income (Loss) $2,611,000 USD 63%
Nonoperating Income (Expense) $194,000 USD -112%
Net Income (Loss) Attributable to Parent $2,805,000 USD 49%
Earnings Per Share, Basic -2 USD/shares 55%
Earnings Per Share, Diluted -2 USD/shares 55%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $2,803,000 USD -32%
Accounts Receivable, after Allowance for Credit Loss, Current $38,000 USD 46%
Assets, Current $3,051,000 USD -30%
Property, Plant and Equipment, Net $3,000 USD -98%
Operating Lease, Right-of-Use Asset $32,000 USD -79%
Assets $3,051,000 USD -30%
Accounts Payable, Current $219,000 USD -38%
Liabilities, Current $263,000 USD -26%
Liabilities $263,000 USD -26%
Retained Earnings (Accumulated Deficit) $397,788,000 USD -0.71%
Stockholders' Equity Attributable to Parent $2,788,000 USD -30%
Liabilities and Equity $3,051,000 USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $867,000 USD -41%
Net Cash Provided by (Used in) Financing Activities $19,000 USD
Common Stock, Shares Authorized 225,000,000 shares 0%
Common Stock, Shares, Issued 1,330,234 shares 46%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2,803,000 USD -32%
Interest Paid, Excluding Capitalized Interest, Operating Activities $13,000 USD
Deferred Tax Assets, Valuation Allowance $60,480,000 USD -7%
Deferred Tax Assets, Gross $60,480,000 USD -7%
Operating Lease, Liability $33,000 USD -79%
Lessee, Operating Lease, Liability, to be Paid $33,000 USD -80%
Operating Lease, Liability, Current $33,000 USD -74%
Lessee, Operating Lease, Liability, to be Paid, Year One $33,000 USD -66%
Deferred Tax Assets, Operating Loss Carryforwards $49,611,000 USD -6.8%
Preferred Stock, Shares Issued 890,345 shares -6.3%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $400,574,000 USD 0.4%
Preferred Stock, Shares Outstanding 890,345 shares -6.3%
Depreciation, Depletion and Amortization $2,000 USD -95%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%